Effect of sorafenib combined with doxorubicin on human breast cancer cell MDA-MB-231 and lung cancer cell A549
ZHOU Xue;WANG Juan;MA Shu-mei;CHEN Xiu-hua;State Key Lab of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry;
Objective To investigate the effect of sorafenib combined with doxorubicin on human breast cancer cell MDA-MB-231 and lung cancer cell A549. Methods To treat with MDA-MB-231cells and A549 cells using different concentrations of sorafenib combined with doxorubicin. ① CCK-8 was used to detect the inhibition rate in 24, 48 and 72 h. ②To investigate the migration of MDA-MB-231 and A549 cells by wound-healing assay. ③The expression of P-ERK and Bcl-2 in MDA-MB-231 cells in 24 h was detected by Westernblot assay. Results Sorafenib combined with doxorubicin could signif icantly suppress the growth of human breast cancer MDA-MB-231 cells in vitro, in a time dependent; after different concentrations of sorafenib combined with doxorubicin treatment of cancer cells in 24 h, the protein expressing of P-ERK and Bcl-2 was signifi cantly lowered. Conclusion Sorafenib combined with doxorubicin might inhibit the proliferation of human breast cancer cells MDA-MB-231 and lung cancer cells A549.
【CateGory Index】： R737.9;R734.2